Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 26.45 $ -0.64 (-2.36 %)    

Friday, 09-Aug-2024 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 26.43
$ 26.43 x 100
$ 26.45 x 175
-- - --
$ 24.53 - $ 39.53
482,367
na
118.94M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/09/2024 21:24:40

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-updates-fy24-revenue-guidance-from-dkk-187b--205b-to-dkk-205b--217b-reflecting-continued-strong-growth-of-darzalex-and-kesimpta-net-sales
Genmab Updates FY24 Revenue Guidance From ...
08/08/2024 15:04:04

Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in o...

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/06/2024 11:29:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-rd-spending-on-new-cancer-products
BioNTech's Q2 Loss Widens Amid Low Demand ...
08/05/2024 11:59:26

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...

Core News & Articles
Genmab Takes Over Acasunlimab Development,...
08/05/2024 09:53:21

 Genmab A/S (NASDAQ: GMAB) announced today that it will assume sole responsibility for the continued development and potential ...

what-8-analyst-ratings-have-to-say-about-genmab
What 8 Analyst Ratings Have To Say About G...
08/01/2024 19:08:11

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/01/2024 10:07:01

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
07/18/2024 12:33:05

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

what-8-analyst-ratings-have-to-say-about-genmab
What 8 Analyst Ratings Have To Say About G...
07/15/2024 17:00:29

rbc-capital-upgrades-genmab-to-outperform
RBC Capital Upgrades Genmab to Outperform
07/15/2024 10:04:13

RBC Capital analyst Alistair Campbell upgrades Genmab (NASDAQ:GMAB) from Sector Perform to Outperform.

reported-earlier-genmabs-epcoritamab-receives-ema-opinion-for-follicular-lymphoma-treatment
Reported Earlier, Genmab's Epcoritamab Rec...
06/28/2024 07:36:11

Genmab A/S (NASDAQ:GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Hu...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway
AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

btig-maintains-buy-on-genmab-raises-price-target-to-47
BTIG Maintains Buy on Genmab, Raises Price...
06/27/2024 12:01:28

BTIG analyst Kaveri Pohlman maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $46 to $47.

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/27/2024 10:31:03

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announced-that-the-us-fda-approved-epkinly-for-the-treatment-of-adults-with-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy
Genmab Announced That The U.S. FDA Approve...
06/27/2024 06:54:13

10-analysts-assess-genmab-what-you-need-to-know
10 Analysts Assess Genmab: What You Need T...
06/20/2024 12:00:25

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/20/2024 10:43:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

truist-securities-maintains-buy-on-genmab-raises-price-target-to-53
Truist Securities Maintains Buy on Genmab,...
06/04/2024 12:54:42

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $5...

genmabs-phase-2-trial-shows-tisotumab-vedotin-achieves-325-objective-response-rate-in-head-and-neck-cancer
Genmab's Phase 2 Trial Shows Tisotumab Ved...
06/03/2024 13:11:09

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/03/2024 10:34:22

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION